Journal of Medicinal Chemistry
Article
(16) DeGoey, D. A.; Randolph, J. T.; Liu, D.; Pratt, J.; Hutchins, C.;
Donner, P.; Krueger, A. C.; Matulenko, M.; Patel, S.; Motter, C. E.;
Nelson, L.; Keddy, R.; Tufano, M.; Caspi, D. D.; Krishnan, P.; Mistry,
N.; Koev, G.; Reisch, T. J.; Mondal, R.; Pilot-Matias, T.; Gao, Y.; Beno,
D. W. A.; Maring, C. J.; Molla, A.; Dumas, E.; Campbell, A.; Williams, L.;
Collins, C.; Wagner, R.; Kati, W. M. Discovery of ABT-267, a Pan-
Genotypic Inhibitor of HCV NS5A. J. Med. Chem. 2014, 57 (5), 2047−
2057.
(17) Keating, G. M. Ledipasvir/Sofosbuvir: A Review of Its Use in
Chronic Hepatitis C. Drugs 2015, 75 (6), 675−685.
(18) A 4-Drug Combination (Viekira Pak) for Hepatitis C. JAMA, J.
Am. Med. Assoc. 2015, 313 (18), 1857−1858 DOI: 10.1001/
jama.2015.4562.
(19) A 4-Drug Combination (Viekira Pak) for Hepatitis C. Med. Lett.
(accessed Dec 6, 2015).
(20) Deeks, E. D. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir:
A Review in Chronic HCV Genotype 1 Infection. Drugs 2015, 75 (9),
1027−1038.
(21) Di Bisceglie, A. M.; Sulkowski, M.; Gane, E.; Jacobson, I. M.;
Nelson, D.; DeSouza, C.; Alves, K.; George, S.; Kieffer, T.; Zhang, E. Z.;
Kauffman, R.; Asmal, M.; Koziel, M. J. VX-222, a Non-Nucleoside NS5B
Polymerase Inhibitor, in Telaprevir-Based Regimens for Genotype 1
Hepatitis C Virus Infection. Eur. J. Gastroenterol. Hepatol. 2014, 26 (7),
761−773.
(22) Biswal, B. K.; Cherney, M. M.; Wang, M.; Chan, L.; Yannopoulos,
C. G.; Bilimoria, D.; Nicolas, O.; Bedard, J.; James, M. N. G. Crystal
Structures of the RNA-Dependent RNA Polymerase Genotype 2a of
Hepatitis C Virus Reveal Two Conformations and Suggest Mechanisms
of Inhibition by Non-Nucleoside Inhibitors. J. Biol. Chem. 2005, 280
(18), 18202−18210.
REFERENCES
■
(1) Gower, E.; Estes, C.; Blach, S.; Razavi-Shearer, K.; Razavi, H.
Global Epidemiology and Genotype Distribution of the Hepatitis C
Virus Infection. J. Hepatol. 2014, 61 (Suppl 1), S45−S57.
(2) Shepard, C. W.; Finelli, L.; Alter, M. J. Global Epidemiology of
Hepatitis C Virus Infection. Lancet Infect. Dis. 2005, 5 (9), 558−567.
(3) Viral Hepatitis Statistics & Surveillance; Division of Viral Hepatitis
and National Center for HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention, Centers for Disease Control: Atlanta, GA, 2014; http://
(4) Lin, K.; Perni, R. B.; Kwong, A. D.; Lin, C. VX-950, a Novel
Hepatitis C Virus (HCV) NS3−4A Protease Inhibitor, Exhibits Potent
Antiviral Activities in HCV Replicon Cells. Antimicrob. Agents
Chemother. 2006, 50 (5), 1813−1822.
(5) Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.;
Chaturvedi, P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C.
A.; Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.;
Luong, Y. P. C.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.;
Wei, Y.; Kwong, A. D.; Lin, C. Preclinical Profile of VX-950, a Potent,
Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3−
4A Serine Protease. Antimicrob. Agents Chemother. 2006, 50 (3), 899−
909.
(6) Kwong, A. D.; Kauffman, R. S.; Hurter, P.; Mueller, P. Discovery
and Development of Telaprevir: An NS3−4A Protease Inhibitor for
Treating Genotype 1 Chronic Hepatitis C Virus. Nat. Biotechnol. 2011,
29 (11), 993−1003.
(7) Njoroge, F. G.; Chen, K. X.; Shih, N.-Y.; Piwinski, J. J. Challenges in
Modern Drug Discovery: A Case Study of Boceprevir, an HCV Protease
Inhibitor for the Treatment of Hepatitis C Virus Infection. Acc. Chem.
Res. 2008, 41 (1), 50−59.
(8) Poordad, F.; McCone, J.; Bacon, B. R.; Bruno, S.; Manns, M. P.;
Sulkowski, M. S.; Jacobson, I. M.; Reddy, K. R.; Goodman, Z. D.;
Boparai, N.; DiNubile, M. J.; Sniukiene, V.; Brass, C. A.; Albrecht, J. K.;
Bronowicki, J.-P. Boceprevir for Untreated Chronic HCV Genotype 1
Infection. N. Engl. J. Med. 2011, 364 (13), 1195−1206.
(23) Wunberg, T.; Baumeister, J.; Gottschling, D.; Henninger, K.;
Koletzki, D.; Pernerstorfer, J.; Urban, A.; Birkmann, A.; Harrenga, A.;
Lobell, M. Alkinyl-Substituted Thiophenes. Patent WO2006072347
(A3), December 7, 2006.
(24) Grimes, R. M.; Hartley, C. D.; Mordaunt, J. E.; Shah, P.; Slater, M.
J.; White, G. V. 2-Carboxy Thiophene Derivatives as Anti Viral Agents.
Patent WO2008059042 (A1), May 22, 2008.
(9) Schlutter, J. Therapeutics: New Drugs Hit the Target. Nature 2011,
̈
474 (7350), S5−S7.
(10) Rosenquist, Å.; Samuelsson, B.; Johansson, P.-O.; Cummings, M.
D.; Lenz, O.; Raboisson, P.; Simmen, K.; Vendeville, S.; de Kock, H.;
Nilsson, M.; Horvath, A.; Kalmeijer, R.; de la Rosa, G.; Beumont-
Mauviel, M. Discovery and Development of Simeprevir (TMC435), a
HCV NS3/4A Protease Inhibitor. J. Med. Chem. 2014, 57 (5), 1673−
1693.
(11) Gentile, I.; Borgia, F.; Buonomo, A. R.; Zappulo, E.; Castaldo, G.;
Borgia, G. ABT-450: A Novel Protease Inhibitor for the Treatment of
Hepatitis C Virus Infection. Curr. Med. Chem. 2014, 21 (28), 3261−
3270.
(12) Sofia, M. J.; Bao, D.; Chang, W.; Du, J.; Nagarathnam, D.;
Rachakonda, S.; Reddy, P. G.; Ross, B. S.; Wang, P.; Zhang, H.-R.;
Bansal, S.; Espiritu, C.; Keilman, M.; Lam, A. M.; Steuer, H. M. M.; Niu,
C.; Otto, M. J.; Furman, P. A. Discovery of a β-D-2′-Deoxy-2′-α-Fluoro-
2′-β-C-Methyluridine Nucleotide Prodrug (PSI-7977) for the Treat-
ment of Hepatitis C Virus. J. Med. Chem. 2010, 53 (19), 7202−7218.
(13) Trivella, J. P.; Gutierrez, J.; Martin, P. Dasabuvir: A New Direct
Antiviral Agent for the Treatment of Hepatitis C. Expert Opin.
Pharmacother. 2015, 16 (4), 617−624.
(14) Link, J. O.; Taylor, J. G.; Xu, L.; Mitchell, M.; Guo, H.; Liu, H.;
Kato, D.; Kirschberg, T.; Sun, J.; Squires, N.; Parrish, J.; Keller, T.; Yang,
Z.-Y.; Yang, C.; Matles, M.; Wang, Y.; Wang, K.; Cheng, G.; Tian, Y.;
Mogalian, E.; Mondou, E.; Cornpropst, M.; Perry, J.; Desai, M. C.
Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A
Inhibitor for the Treatment of Hepatitis C Virus Infection. J. Med. Chem.
2014, 57 (5), 2033−2046.
(25) Lazerwith, S. E.; Lew, W.; Zhang, J.; Morganelli, P.; Liu, Q.;
Canales, E.; Clarke, M. O.; Doerffler, E.; Byun, D.; Mertzman, M.; Ye,
H.; Chong, L.; Xu, L.; Appleby, T.; Chen, X.; Fenaux, M.; Hashash, A.;
Leavitt, S. A.; Mabery, E.; Matles, M.; Mwangi, J. W.; Tian, Y.; Lee, Y.-J.;
Zhang, J.; Zhu, C.; Murray, B. P.; Watkins, W. J. Discovery of GS-9669, a
Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of
Genotype 1 Chronic Hepatitis C Infection. J. Med. Chem. 2014, 57 (5),
1893−1901.
(26) Barnes-Seeman, D.; Boiselle, C.; Capacci-Daniel, C.; Chopra, R.;
Hoffmaster, K.; Jones, C. T.; Kato, M.; Lin, K.; Ma, S.; Pan, G.; Shu, L.;
Wang, J.; Whiteman, L.; Xu, M.; Zheng, R.; Fu, J. Design and Synthesis
of Lactam−thiophene Carboxylic Acids as Potent Hepatitis C Virus
Polymerase Inhibitors. Bioorg. Med. Chem. Lett. 2014, 24 (16), 3979−
3985.
(27) Li, H.; Tatlock, J.; Linton, A.; Gonzalez, J.; Jewell, T.; Patel, L.;
Ludlum, S.; Drowns, M.; Rahavendran, S. V.; Skor, H.; Hunter, R.; Shi,
S. T.; Herlihy, K. J.; Parge, H.; Hickey, M.; Yu, X.; Chau, F.; Nonomiya,
J.; Lewis, C. Discovery of (R)-6-Cyclopentyl-6-(2-(2,6-Diethylpyridin-
4-Yl)ethyl)-3-((5,7-Dimethyl-[1,2,4]triazolo[1,5-A]pyrimidin-2-Yl)-
methyl)-4-Hydroxy-5,6-Dihydropyran-2-One (PF-00868554) as a
Potent and Orally Available Hepatitis C Virus Polymerase Inhibitor. J.
Med. Chem. 2009, 52 (5), 1255−1258.
(28) Howe, A. Y. M.; Bloom, J.; Baldick, C. J.; Benetatos, C. A.; Cheng,
H.; Christensen, J. S.; Chunduru, S. K.; Coburn, G. A.; Feld, B.;
Gopalsamy, A.; Gorczyca, W. P.; Herrmann, S.; Johann, S.; Jiang, X.;
Kimberland, M. L.; Krisnamurthy, G.; Olson, M.; Orlowski, M.;
Swanberg, S.; Thompson, I.; Thorn, M.; Del Vecchio, A. D.; Young, D.
C.; van Zeijl, M.; Ellingboe, J. W.; Upeslacis, J.; Collett, M.; Mansour, T.
S.; O’Connell, J. F. Novel Nonnucleoside Inhibitor of Hepatitis C Virus
RNA-Dependent RNA Polymerase. Antimicrob. Agents Chemother.
2004, 48 (12), 4813−4821.
(15) Lemm, J. A.; Leet, J. E.; O’Boyle, D. R.; Romine, J. L.; Huang, X.
S.; Schroeder, D. R.; Alberts, J.; Cantone, J. L.; Sun, J.-H.; Nower, P. T.;
Martin, S. W.; Serrano-Wu, M. H.; Meanwell, N. A.; Snyder, L. B.; Gao,
M. Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric
Structures. Antimicrob. Agents Chemother. 2011, 55 (8), 3795−3802.
I
J. Med. Chem. XXXX, XXX, XXX−XXX